Research programme: recombinant idursulfase - JCR Pharmaceuticals/GlaxoSmithKline

Drug Profile

Research programme: recombinant idursulfase - JCR Pharmaceuticals/GlaxoSmithKline

Alternative Names: GSK-2788723; iduronate-2-sulfatase; JR-032; recombinant idursulfase; recombinant-iduronate-2-sulfatase

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JCR Pharmaceuticals
  • Developer GlaxoSmithKline KK; JCR Pharmaceuticals
  • Class Iduronate sulfatases
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mucopolysaccharidosis II

Most Recent Events

  • 22 May 2018 Preclinical development is ongoing for Mucopolysaccharidosis-II in Japan (Parenteral) (JCR Pharmaceutical pipeline, May 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-II in Japan (Parenteral)
  • 28 Aug 2012 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top